Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 13Stomach Neoplasms 3Neoplasm Metastasis 3Carcinoma, Hepatocellular 3Esophageal Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Unresectable Locally Advanced or Metastatic Solid Tumors 1Turcot syndrome 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Tertiary Lymphoid Structures 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Osteosarcoma 1Mesothelioma, Malignant 1Melanoma 1Glioblastoma 1Gastrointestinal Neoplasms 1Gastro-enteropancreatic neuroendocrine tumor 1Esophageal Squamous Cell Carcinoma 1Central Nervous System Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Merkel Cell 1Brain Neoplasms 1

Interventions

Nivolumab 9Ipilimumab 4linrodostat 2relatlimab 1regorafenib 1Tetanus Toxoid 1Sorafenib 1Paclitaxel 1Oxaliplatin 1N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 1Gemcitabine 1Cyclophosphamide 1Cisplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Advanced Cancer × regorafenib × Clear all
NCT03994601 2026-01-20

An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers

Bristol-Myers Squibb

Phase 1/2 Completed
219 enrolled 35 charts

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡